Back grey_arrow_rt.gif
Generic Tenofovir Gets FDA Approval
  On April 6, 2010, the Food and Drug Administration granted tentative approval for generic Tenofovir Disoproxil Fumarate Tablets, 300 mg, under expedited review procedures for the President's Emergency Plan for AIDS Relief (PEPFAR). This generic formulation, manufactured by Hetero Drugs, Ltd.,of Hyberdad, India, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.
FDA's tentative approval of this product means that while FDA cannot fully approve the product for sale in the United States because of existing patent protections, it has been shown to meet all of FDA's safety, efficacy and manufacturing quality standards. Tentative approval qualifies the product for purchase outside the United States using PEPFAR funds.
This product is a generic veision of Viread Tablets, 300 mg, a Nucleos ide Reverse Transcriptase Inhibitor (NRTI), made by Gilead Sciences Inc. Patent information is available in the FDA Orange Book.
As with all generic applications, FDA conducts an on-site inspection of each manufacturing facility, and of the facilities performing the bioequivalence studies, to evaluate the ability of the manufacturer to produce a quality product and to assess the quality of the bioequivalence data supporting the application prior to granting approval or tentative approval to these applications.
You can find a complete list of all Approved and Tentatively Approved Antiretrovirals in Association with the President's Emergency Plan3on the FDA web site.
Richard Klein Office of Special Health Issues Food and Drug Administration Kimberly Struble Division of Antiviral Drug Products Food and Drug Administration
  icon paper stack View Older Articles   Back to Top